Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?

"Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?." Leukemia & Lymphoma, 62(14), pp. 3318–3319

Disclosure statement

Jan Philipp Bewersdorf: no conflict of interests. Richard Stone: Abbvie: advisory board; Actinium: advisory board; Arog: advisory board; BMS: advisory board; Boston Pharmaceuticals: advisory board; GSK: AML expert council; Janssen: advisory board; Jazz: advisory board; Novartis: advisory board; Syros: advisory board; Takeda: advisory board, data and safety monitoring board. Martin S. Tallman: Abbvie: research funding; Cellerant: research funding; Orsenix: research funding; ADC Therapeutics: research funding; BioSight: Membership on an entity's Board of Directors or advisory committees and research funding; Glycomimetics: research funding; Rafael: research funding; Amgen: research funding; Bioline rx: Membership on an entity's Board of Directors or advisory committees. Daiichi-Sankyo: Membership on an entity's Board of Directors or advisory committees; KAHR: Membership on an entity's Board of Directors or advisory committees; Rigel: Membership on an entity's Board of Directors or advisory committees; Delta Fly Pharma: Membership on an entity's Board of Directors or advisory committees; Oncolyze: Membership on an entity's Board of Directors or advisory committees; Jazz Pharma: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; UpToDate: Patents & Royalties; Innate Pharmaceuticals: Advisory Board; Kura Oncology: Advisory Board. Maximilian Stahl: No conflict of interests.